Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Testing and Managing Mixed Hyperlipidemia: Challenges and Opportunities

Medically reviewed by 
Testing and Managing Mixed Hyperlipidemia: Challenges and Opportunities

Mixed hyperlipidemia, characterized by elevated levels of cholesterol and triglycerides, stands as a significant risk factor for cardiovascular diseases, which remain the leading cause of death worldwide. Addressing this condition is crucial not just for managing its immediate health implications but also for mitigating long-term risks to heart health. This article aims to provide a comprehensive overview of the challenges in diagnosing mixed hyperlipidemia, outline the current management strategies, and introduce emerging treatments that offer new hope to those affected.

Understanding and managing mixed hyperlipidemia can be complex, but advancements in medical research and treatment options are making it increasingly manageable. As we explore the diagnostic hurdles, effective management techniques, and the latest in therapeutic innovations, our goal is to equip you with the knowledge needed to navigate this condition more effectively. With cardiovascular diseases claiming lives each day, taking informed steps toward managing mixed hyperlipidemia is more important than ever.


What is Mixed Hyperlipidemia? 

Mixed hyperlipidemia, a specific subset of dyslipidemia, is identified by elevated blood lipid levels, specifically when fasting triglycerides exceed 1.7 mmol/L and total cholesterol surpasses 5 mmol/L. This condition is characterized by an increase in both triglycerides and LDL cholesterol, with potential decreases in HDL cholesterol, posing a heightened risk for cardiovascular diseases.

The root causes of mixed hyperlipidemia straddle both genetics and lifestyle. Genetic predispositions play a pivotal role, particularly in cases of combined familial hyperlipidemia, where specific mutations impair the body's lipid regulation mechanisms. Lifestyle factors, including dietary habits, physical activity levels, and tobacco use, also significantly influence lipid profiles. Diets rich in saturated fats can lead to increases in LDL cholesterol and triglycerides, while consistent physical activity has been shown to improve these lipid measures (40,48). 

The prevalence of dyslipidemia is a growing concern, with age being a key factor in its increased occurrence. This condition affects a significant portion of the adult population, highlighting the importance of awareness and management to prevent cardiovascular complications. Despite the challenges in achieving and maintaining optimal lipid levels, understanding the impact of genetics and lifestyle choices on dyslipidemia can empower individuals to make informed decisions about their health (40,48). 

In addition, mixed hyperlipidemia plays a pivotal role in the development of atherosclerosis, a process where lipid deposits build up in the arterial walls, leading to reduced blood flow and increased risk of coronary artery disease and stroke. Elevated levels of triglycerides and LDL cholesterol, characteristic of mixed hyperlipidemia, contribute to the formation of these lipid deposits. Over time, these deposits can harden, narrowing the arteries and limiting oxygen-rich blood flow to the heart and brain. This compromised blood flow significantly elevates the risk of life-threatening events such as heart attacks and strokes (40,48). 

Mixed Hyperlipidemia Symptoms

Physical symptoms of mixed hyperlipidemia are limited, with the most common being the presence of xanthomas on the skin, eyelids, or tendons (40). 

Diagnostic Challenges in Mixed Hyperlipidemia 

Diagnosing mixed hyperlipidemia presents unique challenges, primarily due to its variable presentation and the common overlap with other lipid disorders. Unlike conditions with clear-cut symptoms, mixed hyperlipidemia can be silently progressing, often revealing itself only through targeted lipid profile testing. This variability makes routine screening and early detection critical, yet complicated. The subtlety of its manifestation means many individuals remain undiagnosed until significant complications arise, underscoring the need for heightened awareness among healthcare providers (40).

Current guidelines emphasize the importance of comprehensive lipid panel assessments for adults, recommending baseline screenings to begin as early as 20 years of age, with follow-up intervals based on initial results and individual risk factors. These lipid panels are vital in detecting mixed hyperlipidemia, as they provide a detailed look at all fractions of cholesterol and triglycerides. However, interpreting these results requires careful consideration of the broader clinical context, including family history and lifestyle factors, to differentiate mixed hyperlipidemia from other dyslipidemias (40).

One of the diagnostic hurdles is the influence of acute illnesses, medications, and lifestyle changes on lipid levels, which can temporarily alter the lipid profile and obscure the underlying disorder. This necessitates a careful review of any potential confounding factors and, often, repeat testing under stable conditions to confirm a diagnosis. Additionally, the presence of other conditions like diabetes or metabolic syndrome can complicate the interpretation of lipid profiles, as these conditions often coexist with dyslipidemia, blurring the lines between primary lipid disorders and secondary manifestations (40).

The overlap with other lipid disorders further complicates diagnosis. For instance, distinguishing mixed hyperlipidemia from isolated hypercholesterolemia or hypertriglyceridemia requires a nuanced understanding of lipid metabolism and the specific patterns seen in mixed hyperlipidemia, such as elevated levels of both LDL cholesterol and triglycerides. This complexity highlights the need for a comprehensive approach that considers genetic testing, especially in cases where familial hyperlipidemia is suspected, to tailor management strategies effectively (40).

Mixed Hyperlipidemia Treatment 

Treating mixed hyperlipidemia involves a multifaceted approach, blending lifestyle changes with pharmacological interventions to manage and reduce lipid levels effectively. The initial step typically focuses on lifestyle modifications, including dietary adjustments to increase the intake of vegetables, fruits, and whole grains while maintaining an appropriate calorie intake. Adding moderate to vigorous aerobic physical activity 3 to 4 times a week for at least 40 minutes is also recommended to improve lipid profiles (40,48). 

Diet plays a crucial role in managing dyslipidemia, with a focus on reducing saturated fats and incorporating fiber-rich foods that can help lower cholesterol levels. Exercise complements dietary efforts by aiding weight management and improving the body's lipid utilization (40). 

Pharmacologically, statins are the cornerstone of dyslipidemia treatment, acting by inhibiting the HMG-CoA reductase enzyme, which plays a key role in cholesterol synthesis. Statins are effective in lowering LDL-C, with the intensity of the therapy tailored to the patient's cardiovascular risk profile and specific lipid abnormalities. For individuals with significant atherosclerotic cardiovascular disease (ASCVD) or those with LDL-C levels ≥190 mg/dL, high-intensity statin therapy is often initiated (40). 

For patients not reaching LDL-C targets with statin therapy alone, or for those who are statin-intolerant, additional pharmacological agents may be considered. Ezetimibe, which inhibits cholesterol absorption, can be used alongside statins to achieve further LDL-C reduction. PCSK9 inhibitors, such as evolocumab and alirocumab, offer another layer of treatment by enhancing the liver's ability to remove LDL-C from the blood, significantly lowering LDL-C levels (40). 

Emerging treatments, such as bempedoic acid, target alternative pathways in cholesterol synthesis and are especially useful for patients intolerant to statins. This drug, when used in combination with ezetimibe, provides a viable option for further reducing LDL-C levels in patients who require intensive lipid-lowering therapy (40). 

Omega-3 fatty acids, particularly icosapent ethyl, have been approved for reducing cardiovascular risk in patients with elevated triglycerides, highlighting the role of triglyceride management in comprehensive dyslipidemia care (40). 

For those with familial combined hyperlipidemia, the treatment strategy mirrors that of mixed hyperlipidemia, with an emphasis on lowering increased lipid levels through a combination of statins, fibrates, and lifestyle interventions. Fibrates are particularly useful in targeting high triglyceride levels, enhancing the breakdown of VLDL, and aiding in the reduction of cardiovascular risk. Bile acid sequestrants, though primarily not shown to reduce cardiovascular events directly, play a role in lowering LDL-C by binding bile acids in the intestine, thus reducing cholesterol absorption. Niacin, while sometimes recommended for increasing HDL and lowering LDL and triglyceride levels, has recently been found to contribute to cardiovascular disease. 

Challenges in Managing Mixed Hyperlipidemia

Managing mixed hyperlipidemia involves navigating several specific challenges that impact patient outcomes. Ensuring patient adherence to prescribed lifestyle modifications and medication regimens is a significant hurdle. The complexity of sustaining dietary changes and regular physical activity, combined with the long-term commitment to medication, often leads to lower adherence rates. Moreover, the potential for drug-drug interactions presents a complex challenge, especially in patients with comorbid conditions requiring multiple medications, which can complicate the management plan and affect the efficacy and safety of treatment.

Side effects from lipid-lowering medications, including statins, can further complicate adherence. Statin intolerance, for instance, can manifest through muscle pain or weakness, leading some patients to discontinue therapy without medical consultation. This discontinuation or non-compliance with therapy regimens directly influences patient outcomes, increasing the risk of cardiovascular events associated with unmanaged dyslipidemia.

The importance of patient education and engagement is also an important part of overcoming these challenges. Educating patients about the nature of mixed hyperlipidemia, the risks associated with non-adherence, and the management of potential side effects is crucial. Engaging patients in their care process, through shared decision-making and setting realistic goals, can enhance adherence and outcome. This approach includes discussing the benefits and risks of various treatments, managing expectations regarding the impact of lifestyle changes, and addressing concerns about medication side effects promptly.

Emerging Opportunities and Therapies 

Recent advancements in lipid-lowering therapies have introduced novel agents that offer promising prospects for individuals with mixed hyperlipidemia. PCSK9 inhibitors, such as alirocumab and evolocumab, have shown exceptional efficacy in reducing LDL cholesterol levels. These biologics work by inhibiting the PCSK9 protein, which degrades LDL receptors, thereby enhancing the liver's ability to remove LDL cholesterol from the blood.

Another groundbreaking development is the approval of inclisiran, a small interfering RNA (siRNA) therapy that targets PCSK9 at the mRNA level. This novel mechanism allows for a significant reduction in LDL cholesterol with the convenience of bi-annual dosing, potentially improving patient adherence and outcomes (38). 

Bempedoic acid, targeting the ATP-citrate lyase enzyme involved in cholesterol synthesis, provides an alternative for patients who cannot tolerate statins. Its mechanism complements statins and offers an additional avenue for lowering LDL cholesterol levels in mixed hyperlipidemia cases (38). 

Ezetimibe, which inhibits the intestinal absorption of cholesterol, continues to be a valuable addition to statin therapy, especially in mixed hyperlipidemia where comprehensive lipid control is vital. The combination of ezetimibe with statins or bempedoic acid can lead to further reductions in LDL cholesterol, addressing both components of mixed hyperlipidemia effectively (38). 

Emerging therapies targeting triglycerides, such as volanesorsen and olezarsen, focus on reducing triglyceride-rich lipoproteins by inhibiting the production of apolipoprotein C-III, a key regulator of triglyceride metabolism. These treatments represent a leap forward in managing high triglyceride levels, a challenging aspect of mixed hyperlipidemia (38). 

The potential of ANGPTL3 inhibitors like evinacumab highlights further advances in dyslipidemia treatment. By inhibiting the ANGPTL3 protein, these therapies can lower both LDL cholesterol and triglycerides, addressing the complex lipid profile seen in mixed hyperlipidemia (38). 

Lerodalcibep, utilizing CRISPR-Cas9 technology to inhibit PCSK9 gene expression, and vaccines against PCSK9 promise a future where long-term lipid management could become less reliant on daily medication, revolutionizing the approach to mixed hyperlipidemia (38). 

As these new treatments progress through clinical trials and become integrated into clinical practice, the management of mixed hyperlipidemia will increasingly move towards a more personalized and multidrug approach. This shift reflects a broader trend in medicine towards targeted, mechanism-based therapies that offer improved outcomes and better quality of life for patients with complex lipid disorders (38). 

The Role of Healthcare Providers

Healthcare providers are the frontline in identifying individuals at risk of mixed hyperlipidemia as well as managing the disease. This is accomplished using a combination of patient history, physical examinations, and lipid panel testing to diagnose this disorder. Healthcare providers customize treatment plans to individual patient needs, considering the complexity of mixed hyperlipidemia, which often requires a combination of lifestyle interventions and pharmacotherapy.

Lifestyle modification is the cornerstone of managing mixed hyperlipidemia, and healthcare providers play a critical role in educating patients about the importance of a healthy diet, regular exercise, and smoking cessation. They offer practical advice on dietary changes that lower LDL cholesterol and triglycerides, such as reducing saturated fats and increasing fiber intake. Regular physical activity is encouraged, with providers often recommending specific types and amounts of exercise that can help improve lipid profiles (33). 

Pharmacological treatment is guided by healthcare providers based on the latest guidelines and the patient’s overall cardiovascular risk. They prescribe statins as the first line of therapy for lowering LDL cholesterol, adding ezetimibe or PCSK9 inhibitors when further reduction is needed. For patients with high triglycerides, fibrates, omega-3 fatty acids, or niacin may be considered, often in combination with other lipid-lowering medications (40). 

Healthcare providers monitor the efficacy and safety of prescribed treatments through regular follow-ups, adjusting therapies as needed to achieve lipid targets. They assess potential side effects of medications, such as muscle pain with statins or gastrointestinal issues with fibrates, and manage these side effects to maintain patient adherence to treatment. They also play a critical role in managing the secondary causes of mixed hyperlipidemia, such as diabetes mellitus, hypothyroidism, or obesity. This often involves coordinating care with specialists to address these underlying conditions, which can significantly impact lipid levels.

Patient education and engagement are key responsibilities of healthcare providers. They empower patients with knowledge about their condition, treatment options, and the importance of adherence to both lifestyle changes and medications. Providers can also use motivational interviewing techniques to help patients overcome barriers to lifestyle modifications and medication adherence. Healthcare providers advocate for their patients, helping them navigate the healthcare system, access medications, and connect with support services. They may also involve dietitians, exercise physiologists, or cardiac rehabilitation programs as part of a multidisciplinary approach to care.

Patient Education and Lifestyle Intervention

Managing mixed hyperlipidemia effectively involves teaching patients about their condition and encouraging them to make healthy lifestyle choices. Patient-centered education has been effective in helping patients understand how to lower their cholesterol and triglyceride levels. This approach works best when patients actively participate in their treatment plan, which includes beneficial diet changes, regular exercise, and taking their medications as prescribed. By getting involved, patients are more likely to stick to their treatment over the long term (30). 

One of the main challenges in treating mixed hyperlipidemia is ensuring patients keep up with their lifestyle changes and medication. As discussed, side effects from drugs and interactions between different medications can also make treatment more complicated. Educating patients about these issues is important for success. When patients know what to expect and how to handle potential problems, they're better equipped to manage their condition effectively (30). 

In addition, programs that include shared decision-making and motivational talks have shown positive results. These strategies help patients feel more in control and motivated to improve their health. Incorporating technology into patient education and management plans has also emerged as a valuable tool. Digital platforms like apps and online portals can offer patients easy access to information, reminders for medication, and ways to track their progress. This digital approach complements traditional patient education by providing continuous support and engagement, which is particularly beneficial for managing a long-term condition like mixed hyperlipidemia (30). 

Furthermore, building a strong support system around patients, involving family members and peers, can enhance the effectiveness of lifestyle interventions. Social support not only motivates patients but also provides them with practical assistance in making and maintaining lifestyle adjustments. Health care providers can facilitate support groups or recommend community resources to help patients connect with others facing similar challenges, creating a community of support that fosters positive health behaviors and outcomes (30). 


Key Takeaways

The management of mixed hyperlipidemia presents a multifaceted challenge that healthcare providers are uniquely positioned to address. Through a combination of targeted diagnostic approaches, personalized treatment plans, and a strong emphasis on patient education and lifestyle modification, they can significantly mitigate the risks associated with this condition.

Effective management requires a collaborative effort between patients and healthcare professionals, leveraging both pharmacological interventions and lifestyle changes to achieve optimal lipid levels and reduce cardiovascular risk. The ongoing support and guidance from healthcare providers are crucial in navigating the complexities of treatment adherence and lifestyle adjustments.

As research continues to evolve, so too will the strategies for managing mixed hyperlipidemia. Healthcare providers must stay abreast of the latest developments and incorporate these advances into patient care.

Ultimately, the goal is to enhance the quality of life for individuals with mixed hyperlipidemia through comprehensive, evidence-based, and patient-centered care. With the right approach, the prognosis for patients with mixed hyperlipidemia is increasingly positive, offering hope for those affected by this challenging condition.

The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No items found.
  1. Achuff, J. (2024a, February 12). How to Test and Interpret Total Cholesterol Levels: A Functional Medicine Perspective. Rupa Health.
  2. Achuff, J. (2024b, February 27). How to Lower Your Patient's Triglycerides Using Root Cause Medicine. Rupa Health.
  3. Adam, L., Baretella, O., Feller, M., Blum, M. R., Papazoglou, D., Boland, B., Aujesky, D., Baggio, S., & Rodondi, N. (2023). Statin therapy in multimorbid older patients with polypharmacy- a cross-sectional analysis of the Swiss OPERAM trial population. Frontiers in Cardiovascular Medicine, 10.
  4. Alefishat, E., Jarab, A. S., Al‐Qerem, W., & Abu-Zaytoun, L. (2021). Factors Associated with Medication Non-Adherence in Patients with Dyslipidemia. Healthcare, 9(7), 813.
  5. Alu. (2022, September 15). Why Healthcare Advocacy Is Important. School of Public Health.
  6. Anderson, S. (2023, October 12). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health.
  7. Arteriosclerosis / atherosclerosis - Symptoms and causes - Mayo Clinic. (2022, July 1). Mayo Clinic.
  8. Bischof, G., Bischof, A., & Rumpf, H. (2021). Motivational Interviewing: An Evidence-Based Approach for Use in Medical Practice. Deutsches Arzteblatt International.
  9. Blake, K. (2023, October 12). What Is a Heart Healthy Diet and Who Should Follow One? Rupa Health.
  10. Cholesterol-Lowering Medicines | (2023, May 15). Centers for Disease Control and Prevention.
  11. Christie, J. (2023, March 2). An Integrative and Functional Nutrition Approach to Obesity and Weight Management. Rupa Health.
  12. Cloyd, J. (2023a, March 2). 9 Health Benefits of the DASH Diet. Rupa Health.
  13. Cloyd, J. (2023b, June 20). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health.
  14. Cloyd, J. (2023c, September 13). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health.
  15. Cloyd, J. (2024, January 9). Omega-3 Fatty Acids in Cardiovascular Health: A Functional Medicine Guide. Rupa Health.
  16. Cloyd, K. (2024a, January 9). Cardiovascular Disease and Metabolic Syndrome: Addressing Root Causes with Functional Medicine. Rupa Health.
  17. Cloyd, K. (2024b, February 23). How to Interpret Your Lipid Panel Results. Rupa Health.
  18. Creedon, K. (2023, March 2). Simple Lifestyle Changes That Can Help Keep High Blood Pressure Under Control. Rupa Health.
  19. DeCesaris, L. (2024, January 19). Maximizing Patient Engagement: Innovative Strategies for Functional Medicine Practices. Rupa Health.
  20. DePorto, T. (2023, March 2). What Happens to Our Bodies When We Quit Smoking: A Timeline. Rupa Health.
  21. DePorto, T. (2024, February 12). Omega 3s: The Superfood Nutrient You Need To Know About. Rupa Health.
  22. Drageset, J. (2021). Social Support. In Springer eBooks (pp. 137–144).
  23. Enkhmaa, B., Surampudi, P., Anuurad, E., & Berglund, L. (2018, September 11). Lifestyle Changes: Effect of Diet, Exercise, Functional Food, and Obesity Treatment on Lipids and Lipoproteins. Endotext - NCBI Bookshelf.
  24. Feingold, K. R., & Grunfeld, C. (2022, March 7). The Effect of Inflammation and Infection on Lipids and Lipoproteins. Endotext - NCBI Bookshelf.
  25. Genetic Testing for Familial Hypercholesterolemia | CDC. (n.d.).
  26. Harvard Health. (2019, August 9). Managing statin muscle pain.
  27. Heart disease deaths - Health, United States. (n.d.).
  28. Henry, E. (2023, May 12). How To Use Advanced Lipid Testing To Assess Your Cardiac Risk. Rupa Health.
  29. Herink, M., & Ito, M. K. (2018, May 10). Medication Induced Changes in Lipid and Lipoproteins. Endotext - NCBI Bookshelf.
  30. Ismail, F. Z., Redzuan, A. M., & Chong, W. W. (2022). Patient-centered education in dyslipidemia management: a systematic review. Asian Biomedicine, 16(5), 214–236.
  31. Karanchi, H., Muppidi, V., & Wyne, K. (2023, August 14). Hypertriglyceridemia. StatPearls - NCBI Bookshelf.
  32. Khakham, C. (2023, May 12). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health.
  33. Kirkpatrick, C. F., Sikand, G., Petersen, K. S., Anderson, C. A., Aspry, K., Bolick, J. P., Kris-Etherton, P. M., & Maki, K. C. (2023). Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. Journal of Clinical Lipidology, 17(4), 428–451.
  34. Lipid Disorders in Adults (Cholesterol, Dyslipidemia): Screening. (2013, December 30).
  35. Maholy, N. (2023a, April 28). Integrative Medicine Protocol For Reversing Type 2 Diabetes. Rupa Health.
  36. Maholy, N. (2023b, November 8). Improving Gut Health With Exercise. Rupa Health.
  37. Mannu, G., Zaman, M. J. S., Gupta, A., Rehman, H., & Myint, P. K. (2013). Evidence of Lifestyle Modification in the Management of Hypercholesterolemia. Current Cardiology Reviews, 9(1), 2–14.
  38. Merčep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022). New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review. Pharmaceuticals, 15(7), 839.
  39. Padda, I. S., Fabian, D., & Johal, G. S. (2023, June 3). Familial Combined Hyperlipidemia. StatPearls - NCBI Bookshelf.
  40. Pappan, N., & Rehman, A. (2023, July 10). Dyslipidemia. StatPearls - NCBI Bookshelf.
  41. Paterick, T. E., Patel, N., Tajik, A. J., & Chandrasekaran, K. (2017). Improving Health Outcomes Through Patient Education and Partnerships with Patients. Baylor University Medical Center Proceedings, 30(1), 112–113.
  42. Rippe, J. M. (2018). Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. American Journal of Lifestyle Medicine, 13(2), 204–212.
  43. Singh, G., & Correa, R. (2023, May 1). Fibrate Medications. StatPearls - NCBI Bookshelf.
  44. Statin side effects: Weigh the benefits and risks. (2023, May 27). Mayo Clinic.
  45. Suliman, I., Batarfi, A., Almohammadi, H., Aljeraisi, H., Alnaserallah, H., & Ali, A. (2022). Prevalence of Self-Reported Muscle Pain Among Statin Users From National Guard Hospital, Riyadh. Cureus.
  46. Sweetnich, J. (2023, July 5). Overview of The Liver 101: Top Conditions, Specialty Testing, and Integrative Medicine Treatment Options. Rupa Health.
  47. Sweetnich, J. (2024, January 4). How to Make Sure Your Patients Are Getting Enough Vitamin B3 (Niacin) in Their Diet: Testing, RDAs, and Supplementing. Rupa Health.
  48. Viljoen, A., & Wierzbicki, A. S. (2011). Investigating mixed hyperlipidaemia. The BMJ, 343(aug25 2), d5146.
  49. Wang, Y., & Xu, D. (2017). Effects of aerobic exercise on lipids and lipoproteins. Lipids in Health and Disease, 16(1).
  50. Weinberg, J. L. (2023a, March 2). An Integrative Medicine Approach to Hypothyroidism. Rupa Health.
  51. Weinberg, J. L. (2023b, March 2). How to Test Your Patients for Metabolic Syndrome. Rupa Health.
  52. Weinberg, J. L. (2023c, March 2). What is The Mediterranean Diet? Rupa Health.
  53. Yoshimura, H. (2023a, July 18). Using Functional Medicine As Personalized Medicine. Rupa Health.
  54. Yoshimura, H. (2023b, November 9). The Remarkable Power of Exercise on Our Health: A Comprehensive Overview. Rupa Health.
  55. Zaree, A., Dev, S., Khan, I., Arain, M. A., Rasool, S., Rana, M., Kanwal, K., Bhagat, R., Prachi, F., Puri, P., Varrassi, G., Kumar, S., Khatri, M., & Mohamad, T. (2023). Cardiac Rehabilitation in the Modern Era: Optimizing Recovery and Reducing Recurrence. Cureus.
  56. Ferrell, M., Wang, Z., Anderson, J. T., Li, X. S., Witkowski, M., DiDonato, J. A., Hilser, J. R., Hartiala, J., Haghikia, A., Čajka, T., Fiehn, O., Sangwan, N., Demuth, I., König, M., Steinhagen‐Thiessen, E., Landmesser, U., Tang, W. W., Allayee, H., & Hazen, S. L. (2024). A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nature Medicine.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.